- Home
- RAMP vs RCKT Comparison
RAMP vs RCKT Comparison
Compare RAMP & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- RCKT
- Stock Information
- Founded
- RAMP 2018
- RCKT 1999
- Country
- RAMP United States
- RCKT United States
- Employees
- RAMP N/A
- RCKT N/A
- Industry
- RAMP EDP Services
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- RAMP Technology
- RCKT Health Care
- Exchange
- RAMP Nasdaq
- RCKT Nasdaq
- Market Cap
- RAMP 1.8B
- RCKT 328.6M
- IPO Year
- RAMP 1987
- RCKT N/A
- Fundamental
- Price
- RAMP $26.34
- RCKT $3.22
- Analyst Decision
- RAMP Buy
- RCKT Buy
- Analyst Count
- RAMP 7
- RCKT 13
- Target Price
- RAMP $39.00
- RCKT $12.96
- AVG Volume (30 Days)
- RAMP 634.1K
- RCKT 5.7M
- Earning Date
- RAMP 11-05-2025
- RCKT 11-06-2025
- Dividend Yield
- RAMP N/A
- RCKT N/A
- EPS Growth
- RAMP 147.00
- RCKT N/A
- EPS
- RAMP 0.22
- RCKT N/A
- Revenue
- RAMP $764,441,000.00
- RCKT N/A
- Revenue This Year
- RAMP $10.65
- RCKT N/A
- Revenue Next Year
- RAMP $8.70
- RCKT $108.43
- P/E Ratio
- RAMP $121.41
- RCKT N/A
- Revenue Growth
- RAMP 12.16
- RCKT N/A
- 52 Week Low
- RAMP $22.82
- RCKT $2.19
- 52 Week High
- RAMP $36.08
- RCKT $22.01
- Technical
- Relative Strength Index (RSI)
- RAMP 38.37
- RCKT 49.27
- Support Level
- RAMP $26.89
- RCKT $3.12
- Resistance Level
- RAMP $27.08
- RCKT $3.30
- Average True Range (ATR)
- RAMP 0.71
- RCKT 0.18
- MACD
- RAMP 0.05
- RCKT -0.02
- Stochastic Oscillator
- RAMP 4.20
- RCKT 20.03
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.